Form 4: ICU Medical CEO Jain Reports Vesting of Stock Units

ICU Medical's Chairman and CEO, Vivek Jain, reported the vesting and settlement of performance-based and restricted stock units, along with related tax withholdings, as part of his compensation.

Summary

• Vivek Jain, Chairman and CEO of ICU Medical Inc./DE (ICUI), reported transactions involving common stock on March 15, 2026.
• Acquired 17,100 shares of common stock from the settlement of Performance-based Restricted Stock Units (PRSUs) at a price of $0.0. These PRSUs, granted on March 15, 2023, were earned at 117% of target following performance certification on February 11, 2026.
• Disposed of 9,452 shares of common stock at $125.85 per share to cover tax withholding obligations related to the PRSU settlement.
• Acquired 4,872 shares of common stock from the settlement of Restricted Stock Units (RSUs) at a price of $0.0.
• Disposed of 2,693 shares of common stock at $125.85 per share to cover tax withholding obligations related to the RSU settlement.
• Following these transactions, Vivek Jain directly beneficially owns 126,833 shares of common stock and indirectly owns 152,339 shares through a Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine executive compensation disclosure. The 117% achievement of performance targets for PRSUs is a positive indicator of internal goal attainment, though the overall filing is primarily transactional.

Positives

• Performance-based Restricted Stock Units (PRSUs) granted on March 15, 2023, were earned at 117% of target, indicating strong performance against set metrics.
• The vesting of these units represents a successful achievement of compensation goals for the Chairman and CEO.

Negatives

• Disposition of 9,452 shares of common stock at $125.85 to cover tax withholding related to PRSU settlement.
• Disposition of 2,693 shares of common stock at $125.85 to cover tax withholding related to RSU settlement.

Future Outlook

This filing is a transactional report of insider stock ownership changes and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that this Form 4 filing represents a routine disclosure of executive compensation, specifically the vesting of equity awards. Such transactions are common for publicly traded companies and reflect the pre-scheduled settlement of long-term incentive plans for key executives. It does not indicate any unusual corporate activity or significant shifts in industry trends.

Comparison to Industry Standards

• This type of executive compensation event, involving the vesting of performance-based and restricted stock units, is standard practice across many industries, particularly in the healthcare and medical device sectors where long-term incentives are used to align executive interests with shareholder value.
• Companies like Medtronic (MDT) or Baxter International (BAX) frequently report similar Form 4 filings for their executives, detailing the settlement of equity awards and subsequent tax-related share dispositions.
• The achievement of performance targets, as indicated by the 117% earning rate for PRSUs, is a positive sign of the company's internal goal attainment, comparable to performance metrics often seen in peer companies' compensation structures.

Stakeholder Impact

• Shareholders: The vesting of performance-based units at 117% of target could be viewed positively as it suggests the company met or exceeded internal performance metrics tied to executive incentives. The tax-related dispositions are routine and do not reflect a change in management's confidence.

Key Dates

Recommendation

This Form 4 details routine executive compensation events, specifically the vesting of stock units and subsequent tax-related dispositions. While the 117% achievement of performance targets for PRSUs is a positive indicator of internal goal attainment, the filing does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are pre-scheduled and expected, thus maintaining a 'hold' recommendation.

Keywords

ICU Medical, ICUI, Vivek Jain, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Performance Stock Units, Stock Vesting